Warning: mysqli_query(): (HY000/1030): Got error 28 from storage engine in /home/mmahotstuff3/public_html/wp-includes/wp-db.php on line 1924
EPS for bluebird bio, Inc. (BLUE) Expected At $-2.81 - Money Making Articles Hot Stuff

EPS for bluebird bio, Inc. (BLUE) Expected At $-2.81

October 14, 2018 - By Vivian Park

bluebird bio, Inc. (NASDAQ:BLUE) LogoInvestors sentiment increased to 1.4 in Q2 2018. Its up 0.41, from 0.99 in 2018Q1. It is positive, as 36 investors sold bluebird bio, Inc. shares while 69 reduced holdings. 49 funds opened positions while 98 raised stakes. 51.83 million shares or 0.73% more from 51.45 million shares in 2018Q1 were reported.
Gam Ag holds 0.19% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE) for 35,700 shares. Teacher Retirement Of Texas invested in 0.01% or 10,140 shares. Tci Wealth Advsrs holds 0% or 15 shares in its portfolio. Trust Co Of Vermont has invested 0% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE). Menora Mivtachim invested in 0.63% or 141,700 shares. Citigroup owns 273,285 shares. Us Financial Bank De holds 4,038 shares or 0% of its portfolio. Huntington Retail Bank holds 0% in bluebird bio, Inc. (NASDAQ:BLUE) or 360 shares. Mirae Asset Glob Investments has invested 0.01% in bluebird bio, Inc. (NASDAQ:BLUE). Shell Asset Communications invested in 5,376 shares or 0.02% of the stock. Riverhead Capital Mngmt Limited Liability Company, Delaware-based fund reported 302 shares. Tower Rech Capital Limited Liability Corp (Trc) holds 1,280 shares or 0.01% of its portfolio. Tokio Marine Asset Mgmt Co Ltd stated it has 0.45% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE). Woodstock Corporation reported 6,271 shares. 5,100 are held by Virginia Retirement Et Al.

Analysts expect bluebird bio, Inc. (NASDAQ:BLUE) to report $-2.81 EPS on November, 7.They anticipate $1.08 EPS change or 62.43 % from last quarter’s $-1.73 EPS. After having $-2.91 EPS previously, bluebird bio, Inc.’s analysts see -3.44 % EPS growth. The stock decreased 0.43% or $0.55 during the last trading session, reaching $126.09. About 717,422 shares traded or 7.98% up from the average. bluebird bio, Inc. (NASDAQ:BLUE) has risen 15.36% since October 14, 2017 and is uptrending. It has underperformed by 0.26% the S&P500.

bluebird bio, Inc. (NASDAQ:BLUE) Ratings Coverage

Among 8 analysts covering Bluebird Bio (NASDAQ:BLUE), 5 have Buy rating, 1 Sell and 2 Hold. Therefore 63% are positive. Bluebird Bio had 12 analyst reports since May 2, 2018 according to SRatingsIntel. The firm earned “Hold” rating on Monday, May 7 by Bernstein. On Monday, June 4 the stock rating was maintained by Oppenheimer with “Hold”. BTIG Research maintained bluebird bio, Inc. (NASDAQ:BLUE) rating on Wednesday, May 2. BTIG Research has “Buy” rating and $25000 target. Cantor Fitzgerald maintained bluebird bio, Inc. (NASDAQ:BLUE) on Sunday, June 3 with “Sell” rating. BMO Capital Markets maintained the stock with “Outperform” rating in Thursday, May 3 report. As per Friday, June 1, the company rating was maintained by BTIG Research. The firm earned “Overweight” rating on Thursday, May 31 by PiperJaffray. On Friday, June 15 the stock rating was maintained by BTIG Research with “Buy”. The stock of bluebird bio, Inc. (NASDAQ:BLUE) has “Hold” rating given on Friday, June 15 by Oppenheimer. Evercore upgraded it to “Outperform” rating and $230 target in Tuesday, June 19 report.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer in Cambridge, Massachusetts and Seattle, Washington. The company has market cap of $6.83 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent ??-thalassemia, and severe sickle cell disease. It currently has negative earnings. The company's lead product candidate in oncology is bb2121, a chimeric antigen receptor T cell product candidate that is in a Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaborations with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus.

More notable recent bluebird bio, Inc. (NASDAQ:BLUE) news were published by: Fool.com which released: “Here’s Why bluebird bio Dropped 13.3% in September” on October 11, 2018, also Streetinsider.com with their article: “bluebird bio (BLUE) Granted EMA Approval for Marketing Authorization of LentiGlobin Gene Therapy” published on October 05, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on September 21, 2018. More interesting news about bluebird bio, Inc. (NASDAQ:BLUE) were released by: Fool.com and their article: “Why bluebird and Celgene Should Worry About Amgen’s Latest Clinical Victory” published on September 14, 2018 as well as Seekingalpha.com‘s news article titled: “Orchard Rx files for IPO of American shares” with publication date: October 04, 2018.

bluebird bio, Inc. (NASDAQ:BLUE) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Warning: mysqli_query(): (HY000/1030): Got error 28 from storage engine in /home/mmahotstuff3/public_html/wp-includes/wp-db.php on line 1924